CBD Synergies-AX Gummies References

[1] Pacher P et al. Modulating the endocannabinoid system in human health and disease–successes and failures. FEBS J. 2013; 280(9): 1918-43.

[2] McPartland JM et al. Care and feeding of the endocannabinoid system: a systematic review of potential clinical interventions that upregulate the endocannabinoid system. PLoS One. 2014; 9(3): e89566.

[3] Devane WA et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science. 1992; 258 (5090): 1946-1949.

[4] Morales P, et al. Molecular targets of the phytocannabinoids. Prog Chem Org Nat Prod. 2017; 103: 103-131.

[5] Citti C et al. Medicinal cannabis: Principal cannabinoids concentration and their stability evaluated by high-performance liquid chromatography coupled to diode array and quadrupole time of flight mass spectrometry method. J Pharm Biomed Anal. 2016; 128:201-209.

[6] Turner SE. Molecular pharmacology of phytocannabinoids. Prog Chem Org Nat Prod. 2017; 103: 61-101.

[7] Ligresti A. From phytocannabinoids to cannabinoid receptors and endocannabinoids: pleiotropic physiological and pathological roles through complex pharmacology. Physiol Rev. 2016; 96(4): 1593-659.

[8] Mechoulam R. Cannabidiol: an overview of some pharmacological aspects. J Clin Pharmacol. 2002; 42(S1): 11S-19S.

[9] El-Alfy AT et al. Antidepressant-like effect of19 -tetrahydrocannabinol and other cannabinoids isolated from Cannabis sativa L. Pharmacol Biochem Behav. 2010; 95: 434–442

[10] Ashton CH et al. Endocannabinoid system dysfunction in mood and related disorders. Acta Psychiatr Scand. 2011; 124(4): 250-61

[11] Korem N et al. Targeting the endocannabinoid system to treat anxiety-related disorders. J Basic Clin Physiol Pharmacol. 2016; 27(3): 193-202.

[12] Blessing EM et al. Cannabidiol as a potential treatment for anxiety disorders. Neurotherapeutics. 2015; 12(4): 825–836

[13] Soares VP et al. Evidence for the antipanic actions of cannabidiol. Current Neuropharmacology. 2017; 15: 291–299.

[14] Crippa JAS et al. Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary report. Journal of Psychopharmacology. 2011; 25: 121–130.

[15] Linares IMP et al. No acute effects of cannabidiol on the sleep-wake cycle of healthy subjects: a randomized, double-blind, placebo-controlled, crossover study. Front Pharmacol. 2018; 9: 315.

[16] Baldwin D et al. The role of serotonin in depression and anxiety. Int Clin Psychopharmacol. 1995; Suppl 4: 41-5.

[17] Birdsall TC. 5-Hydroxytryptophan: a clinically-effective serotonin precursor. Altern Med Rev. 1998; 3(4): 271-80.

[18] Möhler H. The GABA system in anxiety and depression and its therapeutic potential. Neuropharmacology. 2012; 62(1): 42-53. doi: 10.1016/j.neuropharm.2011.08.040.

[19] Lydiard RB. The role of GABA in anxiety disorders. J Clin Psychiatry. 2003; 64 Suppl 3: 21-7.

[20] Abdou AM. Relaxation and immunity enhancement effects of gamma-aminobutyric acid (GABA) administration in humans. Biofactors. 2006; 26(3): 201-8.

[21] Nobre AC et al. L-theanine, a natural constituent in tea, and its effect on mental state. Asia Pac J Clin Nutr. 2008; 17 Suppl 1: 167-168.

[22] Haskell CF et al. The effects of L-theanine, caffeine, and their combination on cognition and mood. Biol Psychol. 2008; 77(2): 113-122.

[23] Kimura K et al. L-Theanine reduces psychological and physiological stress responses. Biol Psychol. 2007; 74(1): 39–45.

[24] Nathan PJ et al. The neuropharmacology of L-theanine(N-ethyl-L-glutamine): a possible neuroprotective and cognitive enhancing agent. J Herb Pharmacother. 2006; 6(2): 21-30.

[25] Shi Y. Herbal insomnia medications that target GABAergic systems: a review of the psychopharmacological evidence. Curr Neuropharmacol. 2014; 12(3): 289-302.

[26] Hui KM, et al. Anxiolytic effect of wogonin, a benzodiazepine receptor ligand isolated from Scutellaria baicalensis Georgi. Biochem Pharmacol. 2002; 64(9): 1415-1424.